ALLMedicine™ Hyperphosphatemia Center

Jun 21st, 2022 - This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).

Jun 20th, 2022 - Laboratory Studies Perform a CBC count to screen for iron deficiency anemia. Perform a fecal occult blood test to evaluate for GI bleeding. Perform a urinalysis to screen for urinary tract hemorrhage. Obtain serum lipid levels. Pseudoxanthoma elas...

Jun 18th, 2022 - Nutritional interventions have been envisaged to improve hyperphosphatemia and malnutrition, two important risk factors associated with mortality in dialysis patients. We evaluated the effects of egg white consumption on serum phosphate and malnut...

Jun 16th, 2022 - In patients with chronic kidney disease (CKD), hyperphosphatemia is associated with several adverse outcomes, including bone fragility and progression of kidney and cardiovascular disease. However, there is a knowledge gap regarding phosphate bala...

Jun 10th, 2022 - PRIMARY OBJECTIVE: I. Evaluate the tolerability of infigratinib in patients with low-grade and high-grade platinum ineligible upper tract urothelial carcinoma (UTUC). SECONDARY OBJECTIVES: I. Assess tolerability in those with GFR 30-49. II. Evalua...

Jun 21st, 2022 - This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).

Jun 10th, 2022 - PRIMARY OBJECTIVE: I. Evaluate the tolerability of infigratinib in patients with low-grade and high-grade platinum ineligible upper tract urothelial carcinoma (UTUC). SECONDARY OBJECTIVES: I. Assess tolerability in those with GFR 30-49. II. Evalua...

May 25th, 2022 - The working hypotheses are listed as follows: Hyperphosphatemia is an important problem in the CKD realm, but difficult to manage because patients are often not aware of its importance. In addition, current clinical practice does not allow nephrol...

May 19th, 2022 - Secondary Hyperparathyroidism (SHPT) is a common and severe manifestation of chronic kidney disease (CKD), especially in end-stage renal disease (ESRD) patients. SHPT is characterized by elevated parathyroid hormone (PTH) synthesis and secretion a...

Apr 15th, 2022 - Cardiovascular disease (CVD) is the most common cause of morbidity and mortality among patients with end-stage renal disease (ESRD) on hemodialysis (HD). CVD are present since the early stages of chronic kidney disease (CKD) and reach around 30 to...

Jan 25th, 2022 - The FGFR TKI erdafitinib (Balversa) continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alter...

Dec 23rd, 2021 - THE DIAGNOSIS: Acquired Perforating Disorder of Renal Disease A papule with the central plug removed left a pitlike depression, representing Kyrle disease (Figure 1). A punch biopsy of the left forearm revealed epidermal hyperplasia (Figure 2A) su.

Oct 6th, 2021 - With the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates (ADCs), the metastatic urothelial cancer treatment paradigm has dramatically evolved, according to Praful K. Ravi, MD, and even more approaches continue to emerge...

Sep 22nd, 2021 - Erdafitinib (Balversa) in combination with cetrelimab (JNJ-63723283) displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma (mUC) harboring FGFR alterations, according to the first results fr...

Aug 5th, 2021 - The US Food and Drug Administration (FDA) is asking for an additional clinical trial to demonstrate greater benefits of tenapanor before it can decide on approval of the drug for the control of serum phosphorus in adults with chronic kidney diseas...